Capmatinib Dosage Guidelines and Dose Adjustment Strategies

Capmatinib (Capmatinib) is a therapeutic drug for patients with non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations. Doctors will decide whether to treat capmatinib based on this specific mutation in a patient's tumor or plasma sample. If the mutation is not detected in the plasma sample, or if conditions permit, the doctor may recommend further detailed testing of the tumor tissue.

Capmatinib is an oral medication taken twice daily. You can choose to take it with food or alone. The recommended dose of capmatinib is 400 mg orally twice daily. Patients should swallow capmatinib tablets whole and do not break, crush, or chew the tablets. If the patient misses a dose of medication or vomits after taking the medication, there is no need to make up the dose. Instead, the patient should wait until the next scheduled medication time to continue taking the medication to maintain the stability of the medication and the therapeutic effect.

During capmatinib treatment, if adverse reactions occur, the doctor may adjust the drug dosage based on the patient's tolerance. The initial adjustment will usually be reduced to 300 mg twice a day; if further reduction is required, it will be adjusted to 200 mg twice a day. For patients who cannot adapt to the 200 mg dose twice daily, doctors may recommend permanently discontinuing capmatinib and exploring other treatment options suitable for the patient

In summary, capmatinib is a targeted drug for the treatment of MET exon 14 skipping mutations. Its administration method and dosage adjustment should strictly follow the doctor's guidance. Patients should follow medical advice during use, have regular follow-up visits, and promptly report any discomfort or side effects to the doctor so that the treatment plan can be adjusted in a timely manner to ensure the effectiveness and safety of the treatment.